Methyl morpholine oxide → (2S,3S,4S,5R,6S)-6-{2-[2'-(3-Benzyl-1-ethyl-ureidomethyl)-6-methoxy-4'-trifluoromethyl-biphenyl-3-yl]-acetoxy}-3,4,5-trihydroxy-tetrahydro-pyran-2-carboxylic acid benzyl ester

HRID 563837노트

반응식

HRID 563837 반응식
[CH2:1]([NH:8][C:9](=[O:36])[N:10]([CH2:13][C:14]1[CH:19]=[C:18]([C:20]([F:23])([F:22])[F:21])[CH:17]=[CH:16][C:15]=1[C:24]1[C:29]([O:30][CH3:31])=[CH:28][CH:27]=[C:26]([CH2:32][C:33]([OH:35])=[O:34])[CH:25]=1)[CH2:11][CH3:12])[C:2]1[CH:7]=[CH:6][CH:5]=[CH:4][CH:3]=1.[CH2:37]([O:44][C:45]([C@@H:47]1[C@@H:52]([OH:53])[C@H:51]([OH:54])[C@@H:50]([OH:55])[C@H:49](O)[O:48]1)=[O:46])[C:38]1[CH:43]=[CH:42][CH:41]=[CH:40][CH:39]=1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.C[N+]1([O-])CCOCC1>CC#N>[CH2:37]([O:44][C:45]([C@@H:47]1[C@@H:52]([OH:53])[C@H:51]([OH:54])[C@@H:50]([OH:55])[C@H:49]([O:34][C:33](=[O:35])[CH2:32][C:26]2[CH:25]=[C:24]([C:15]3[CH:16]=[CH:17][C:18]([C:20]([F:22])([F:23])[F:21])=[CH:19][C:14]=3[CH2:13][N:10]([CH2:11][CH3:12])[C:9]([NH:8][CH2:1][C:2]3[CH:3]=[CH:4][CH:5]=[CH:6][CH:7]=3)=[O:36])[C:29]([O:30][CH3:31])=[CH:28][CH:27]=2)[O:48]1)=[O:46])[C:38]1[CH:39]=[CH:40][CH:41]=[CH:42][CH:43]=1

참가 물질

6

실험 절차

[2′-(3-Benzyl-1-ethyl-ureidomethyl)-6-methoxy-4′-trifluoromethyl-biphenyl-3-yl]-acetic acid (0.110 g, 0.2 mmol), (2S,3S,4S,5R,6R)-3,4,5,6-tetrahydroxy-tetrahydro-pyran-2-carboxylic acid benzyl ester (0.060 g, 0.2 mmol), HATU (0.026 g, 0.2 mmol), and N-methylmorpholine-N-oxide (0.05 mL, 0.4 mmol) were combined in MeCN (2 mL) and stirred for 2 days at room temperature. The mixture was concentrated, and the residue was purified by preparative HPLC to give the title compound.

후처리

  1. concentrationThe mixture was concentrated
  2. customthe residue was purified by preparative HPLC

출처 및 근거

ORD 기록
ord-3b59b7eadfad4c0fb3f27b75652f6e6e
출처 데이터셋
uspto-grants-2011_11
특허 번호
US08067445B2

반응 노트

불러오는 중…